Concurrent Use of Entresto and Candesartan in CKD Patients
No, Entresto (sacubitril/valsartan) and candesartan should NOT be used together in patients with chronic kidney disease, as this constitutes dual blockade of the renin-angiotensin-aldosterone system (RAAS), which is contraindicated and potentially harmful. 1, 2, 3
Why This Combination is Contraindicated
Guideline-Based Prohibition
The ACC/AHA explicitly states that simultaneous use of an ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and is not recommended (Class III: Harm recommendation). 1, 2
The FDA label for sacubitril/valsartan specifically warns to "avoid use of sacubitril and valsartan with an ARB, because sacubitril and valsartan contains the angiotensin II receptor blocker valsartan." 3 Since candesartan is an ARB, this creates dual ARB blockade.
The ESC guidelines recommend sacubitril/valsartan instead of ACE inhibitors in heart failure patients with diabetes, not in addition to other RAAS blockers. 4
Specific Risks in CKD Patients
CKD patients face amplified risks from dual RAAS blockade:
Acute renal failure risk: Dual blockade significantly increases the risk of acute kidney injury, particularly in patients with bilateral renal artery stenosis or pre-existing renal impairment. 1, 2
Hyperkalemia: Both agents decrease potassium excretion, and CKD patients already have impaired potassium handling. The combination dramatically increases hyperkalemia risk, especially with eGFR <60 mL/min/1.73 m². 1, 2, 5, 3
Hypotension: Dual RAAS blockade causes excessive blood pressure reduction, which can further compromise renal perfusion in CKD patients. 6
Evidence from combination studies: A 2010 study of enalapril plus candesartan in CKD stages 3-5 found that 45% of patients could not tolerate dual blockade, primarily due to loss of renal function (57% of intolerant patients) or hypotension. 7
The Correct Approach: Substitution, Not Addition
Entresto should replace candesartan, not be added to it:
Sacubitril/valsartan is recommended as a replacement for ACE inhibitors or ARBs in heart failure with reduced ejection fraction (HFrEF) patients who remain symptomatic despite optimal therapy. 4
When transitioning from candesartan to Entresto, discontinue candesartan and initiate sacubitril/valsartan after an appropriate washout period to avoid dual RAAS blockade. 3
The PARADIGM-HF trial, which established sacubitril/valsartan's superiority, compared it to enalapril as monotherapy, not combination therapy. 5, 8
Safety Profile of Entresto Alone in CKD
When used as monotherapy (replacing other RAAS blockers), sacubitril/valsartan has demonstrated acceptable safety in CKD:
A 2024 meta-analysis showed sacubitril/valsartan prevented serum creatinine elevation and reduced >50% eGFR decline compared to ACE inhibitors/ARBs in CKD patients. 6
Real-world data in CKD stages 3-4 showed stable renal function after 6 months of sacubitril/valsartan monotherapy, with only 10.6% discontinuation rate. 9
A retrospective analysis in CKD stages III-V found no significant change in eGFR at 90 days, with hyperkalemia >5.5 mEq/L occurring in only 4% of patients. 10
Critical Monitoring if Entresto is Used in CKD
If transitioning from candesartan to Entresto in CKD patients, monitor closely:
Serum potassium and renal function within 1-2 weeks after initiation and after each dose adjustment. 11, 5
Blood pressure including orthostatic measurements to detect symptomatic hypotension. 11, 5
Avoid concurrent potassium supplements, potassium-sparing diuretics, salt substitutes, and NSAIDs, which further increase hyperkalemia risk. 5, 3
Patients with diabetes, eGFR <30 mL/min, or on mineralocorticoid receptor antagonists require particularly vigilant surveillance. 11, 5